Tandem Stock Analysis


USD 42.62  0.57  1.36%   

The modest gains experienced by current holders of Tandem Diabetes Care created some momentum for stakeholders as it was traded today as low as 41.1 and as high as 42.68 per share. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.7. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Tandem Diabetes Care partners.
Additionally, take a look at World Market Map.
The Tandem Diabetes stock analysis report makes it easy to digest most publicly released information about Tandem Diabetes and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Tandem Stock analysis module also helps to analyze the Tandem Diabetes price relationship with some important fundamental indicators such as market cap and management efficiency.

Tandem Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 494.25. Tandem Diabetes Care last dividend was issued on the 10th of October 2017. The entity had 1:10 split on the 10th of October 2017. Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about Tandem Diabetes Care contact Kim Blickenstaff at 858 366 6900 or learn more at https://www.tandemdiabetes.com.

Tandem Diabetes Care Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Tandem Diabetes' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Tandem Diabetes Care or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Tandem Diabetes Care has very high historical volatility over the last 90 days
Over 99.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Exercise or conversion by Leigh Vosseller of 406 shares of Tandem Diabetes subject to Rule 16b-3

Tandem Diabetes Care Upcoming and Recent Events

Earnings reports are used by Tandem Diabetes to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tandem Diabetes previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Tandem Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.7 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tandem Diabetes's market, we take the total number of its shares issued and multiply it by Tandem Diabetes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Tandem Profitablity

Tandem Diabetes' profitability indicators refer to fundamental financial ratios that showcase Tandem Diabetes' ability to generate income relative to its revenue or operating costs. If, let's say, Tandem Diabetes is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Tandem Diabetes' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Tandem Diabetes' profitability requires more research than a typical breakdown of Tandem Diabetes' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.04) %, which suggests for every $100 dollars of sales, it generated a net operating loss of 0.0.
Last ReportedProjected for 2022
Return on Investment 3.53  3.81 
Return on Average Assets 1.92  2.07 
Return on Average Equity 3.89  4.20 
Return on Invested Capital(0.67) (0.72) 
Return on Sales(0.85) (0.92) 

Management Efficiency

The entity has return on total asset (ROA) of (0.0206) % which means that it has lost $0.0206 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.1674) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes management efficiency ratios could be used to measure how well tandem diabetes care manages its routine affairs as well as how well it operates its assets and liabilities. Tandem Diabetes Return on Investment is relatively stable at the moment as compared to the past year. The company's current value of Return on Investment is estimated at 3.81. Return on Average Assets is expected to hike to 2.07 this year, although the value of Return on Invested Capital will most likely fall to (0.72) . Tandem Diabetes Return on Average Assets are relatively stable at the moment as compared to the past year. The company's current value of Return on Average Assets is estimated at 2.07. Tangible Assets Book Value per Share is expected to hike to 4.79 this year, although the value of Revenue to Assets will most likely fall to 0.69.
Last ReportedProjected for 2022
Book Value per Share 1.89  2.04 
Enterprise Value over EBIT(4.60) (4.96) 
Enterprise Value over EBITDA(6.12) (6.60) 
Price to Book Value 5.04  4.92 
Tangible Assets Book Value per Share 4.67  4.79 
Enterprise Value305.5 M293.4 M
Tangible Asset Value110.4 M102.6 M

Technical Drivers

As of the 2nd of December, Tandem Diabetes has the Risk Adjusted Performance of 0.0214, semi deviation of 5.83, and Coefficient Of Variation of 10664.55. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tandem Diabetes Care, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Tandem Diabetes Care, which can be compared to its competition. Please validate Tandem Diabetes Care variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Tandem Diabetes is priced more or less accurately, providing market reflects its prevalent price of 42.62 per share. Given that Tandem Diabetes Care has jensen alpha of (0.16), we advise you to double-check Tandem Diabetes Care's current market performance to make sure the company can sustain itself at a future point.

Tandem Diabetes Care Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Tandem Diabetes double smoothed mean price over a specified number of previous prices (i.e., averaged twice).

Tandem Diabetes Care Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tandem Diabetes insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leigh Vosseller over two weeks ago via Macroaxis 
Exercise or conversion by Leigh Vosseller of 163 shares of Tandem Diabetes subject to Rule 16b-3
Leigh Vosseller over three weeks ago via Macroaxis 
Exercise or conversion by Leigh Vosseller of 407 shares of Tandem Diabetes subject to Rule 16b-3
Leal James over three months ago via Macroaxis 
Exercise or conversion by Leal James of 309 shares of Tandem Diabetes subject to Rule 16b-3
Leal James over three months ago via Macroaxis 
Exercise or conversion by Leal James of 168 shares of Tandem Diabetes subject to Rule 16b-3
Howell Peyton R over three months ago via Macroaxis 
Exercise or conversion by Howell Peyton R of 949 shares of Tandem Diabetes subject to Rule 16b-3
Kim Blickenstaff over three months ago via Macroaxis 
Tandem Diabetes exotic insider transaction detected
Malagueira Joao Paulo Falcao over three months ago via Macroaxis 
Acquisition by Malagueira Joao Paulo Falcao of 5247 shares of Tandem Diabetes subject to Rule 16b-3
Cha Myoungil over three months ago via Macroaxis 
Acquisition by Cha Myoungil of 5247 shares of Tandem Diabetes subject to Rule 16b-3
Mcgroddygoetz Kathleen over three months ago via Macroaxis 
Exercise or conversion by Mcgroddygoetz Kathleen of 1220 shares of Tandem Diabetes subject to Rule 16b-3
Leal James over six months ago via Macroaxis 
Exercise or conversion by Leal James of 310 shares of Tandem Diabetes subject to Rule 16b-3
Leal James over six months ago via Macroaxis 
Acquisition by Leal James of 9669 shares of Tandem Diabetes subject to Rule 16b-3
Sodhi Rajwant over six months ago via Macroaxis 
Exercise or conversion by Sodhi Rajwant of 735 shares of Tandem Diabetes subject to Rule 16b-3

Tandem Diabetes Predictive Daily Indicators

Tandem Diabetes intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tandem Diabetes stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tandem Diabetes Forecast Models

Tandem Diabetes time-series forecasting models is one of many Tandem Diabetes' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tandem Diabetes' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tandem Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tandem Diabetes prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tandem shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Tandem Diabetes. By using and applying Tandem Stock analysis, traders can create a robust methodology for identifying Tandem entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 3.22  3.48 
EBITDA Margin 4.69  5.06 
Gross Margin 53.53  57.76 
Profit Margin 2.21  2.39 

Current Tandem Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tandem analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tandem analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Tandem Diabetes Care current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tandem analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tandem stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tandem Diabetes Care, talking to its executives and customers, or listening to Tandem conference calls.
Tandem Analyst Advice Details

Tandem Stock Analysis Indicators

Tandem Diabetes Care stock analysis indicators help investors evaluate how Tandem Diabetes stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tandem Diabetes shares will generate the highest return on investment. By understating and applying Tandem Diabetes stock analysis, traders can identify Tandem Diabetes position entry and exit signals to maximize returns.
Begin Period Cash Flow94613000.00
Logo U R LimglogosUSTNDM.png
Common Stock Shares Outstanding60990000.00
Total Stockholder Equity433112000.00
DescriptionTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The
Total Cashflows From Investing Activities-186876000.00
Tax Provision335000.00
Quarterly Earnings Growth Y O Y-0.37
Property Plant And Equipment Net77889000.00
Retained Earnings-634595000.00
Cash And Short Term Investments623811000.00
Retained Earnings Total Equity-634595000.00
Accounts Payable28032000.00
Net Debt243487000.00
50 Day M A47.193
Total Current Liabilities131856000.00
Currency CodeUSD
Other Operating Expenses680146000.00
Non Current Assets Total93617000.00
Forward Price Earnings1111.1111
Common Stock Total Equity64000.00
Non Currrent Assets Other9092000.00
Additionally, take a look at World Market Map. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes Care price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
2.7 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine Tandem Diabetes value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.